$GFLT
GenFlat Holdings, Inc. Stock $gflt

$gflt Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000165495421011307 Filed on October 25, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2021 Q1
Revenue	$13.29K	$9.245K
YoY Change		360.18%
Cost Of Revenue	$13.29K	$9.245K
YoY Change		360.18%
Gross Profit	$0.00	$0.00
YoY Change
Gross Profit Margin	0.0%	0.0%
Selling, General & Admin	$217.9K	$179.4K
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$217.9K	$179.4K
YoY Change	263.67%	-87.81%
Operating Profit	-$204.6K	-$170.2K
YoY Change	241.49%	-88.42%
Interest Expense	$8.547K	$8.492K
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$5.555K	-$5.468K
YoY Change
Pretax Income	-$210.1K	-$175.6K
YoY Change
Income Tax		-$5.468K
% Of Pretax Income
Net Earnings	-$210.1K	-$175.6K
YoY Change	250.76%	-88.05%
Net Earnings / Revenue	-1581.18%	-1899.62%
Basic Earnings Per Share	-$0.01	-$0.01
Diluted Earnings Per Share	-$0.01	-$0.01
COMMON SHARES
Basic Shares Outstanding	20.82M shares	20.85M shares	20.85M shares
Diluted Shares Outstanding	20.85M shares	20.85M shares

Balance Sheet

Concept	2021 Q4	2021 Q3	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$15.01K	$101.2K
YoY Change
Cash & Equivalents	$15.01K	$101.2K	$35.06K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$168.6K	$306.8K	$35.06K
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment	$9.970K	$12.60K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.050K	$2.050K	$0.00
YoY Change
Total Long-Term Assets	$870.0K	$872.6K	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$168.6K	$306.8K	$35.06K
Total Long-Term Assets	$870.0K	$872.6K	$0.00
Total Assets	$1.039M	$1.179M	$35.06K
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$85.22K	$79.11K	$36.49K
YoY Change
Accrued Expenses	$31.73K	$33.95K	$35.18K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$325.0K	$300.0K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$452.6K	$424.5K	$71.67K
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities		$2.030K
YoY Change
Total Long-Term Liabilities	$0.00	$2.025K	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$452.6K	$424.5K	$71.67K
Total Long-Term Liabilities	$0.00	$2.025K	$0.00
Total Liabilities	$452.6K	$426.5K	$71.67K
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings	-$2.374M	-$2.164M	-$1.647M
YoY Change
Common Stock	$20.85K	$20.85K	$19.59K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$585.9K	$752.9K	-$36.61K
YoY Change
Total Liabilities & Shareholders Equity	$1.039M	$1.179M	$35.06K
YoY Change

Cashflow Statement

Concept	2021 Q4	2021 Q3
OPERATING ACTIVITIES
Net Income	-$210.1K	-$175.6K
YoY Change	250.76%	-88.05%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$116.2K	-$120.0K
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$5.000K	-$200.0K
YoY Change
Cash From Investing Activities	$5.000K	-$200.0K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	25.00K	386.2K
YoY Change
NET CHANGE
Cash From Operating Activities	-116.2K	-120.0K
Cash From Investing Activities	5.000K	-200.0K
Cash From Financing Activities	25.00K	386.2K
Net Change In Cash	-86.20K	66.16K
YoY Change
FREE CASH FLOW
Cash From Operating Activities	-$116.2K	-$120.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	20821000	shares
CY2021Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	101208	USD
CY2021Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	35055	USD
CY2021Q3	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	200000	USD
CY2021Q1	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	0	USD
CY2021Q3	us-gaap	Interest Receivable InterestReceivable	5556	USD
CY2021Q1	us-gaap	Interest Receivable InterestReceivable	0	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	306764	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	35055	USD
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2050	USD
CY2021Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	12595	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	USD
CY2021Q3	us-gaap	Indefinite Lived License Agreements IndefiniteLivedLicenseAgreements	857990	USD
CY2021Q1	us-gaap	Indefinite Lived License Agreements IndefiniteLivedLicenseAgreements	0	USD
CY2021Q3	us-gaap	Noncurrent Assets NoncurrentAssets	872635	USD
CY2021Q1	us-gaap	Noncurrent Assets NoncurrentAssets	0	USD
CY2021Q3	us-gaap	Assets Assets	1179399	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	36486	USD
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	79106	USD
CY2021Q1	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
CY2021Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	50000	USD
CY2021Q1	us-gaap	Assets Assets	35055	USD
CY2021Q1	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	752851	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	424523	USD
CY2021Q3	us-gaap	Notes Payable Current NotesPayableCurrent	250000	USD
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	33950	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	35181	USD
CY2021Q3	us-gaap	Accrued Reclamation Costs Current AccruedReclamationCostsCurrent	11467	USD
CY2021Q1	us-gaap	Accrued Reclamation Costs Current AccruedReclamationCostsCurrent	0	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	71667	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2025	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2021Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2025	USD
CY2021Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	0	USD
CY2021Q3	us-gaap	Liabilities Liabilities	426548	USD
CY2021Q1	us-gaap	Liabilities Liabilities	71667	USD
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20853000	shares
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19590000	shares
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	20853	USD
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	19590	USD
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2895517	USD
CY2021Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1591283	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2163519	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1647485	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-36612	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1179399	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	35055	USD
CY2021Q3	us-gaap	Cost Of Revenue CostOfRevenue	9245	USD
CY2020Q3	us-gaap	Cost Of Revenue CostOfRevenue	2009	USD
	us-gaap	Cost Of Revenue CostOfRevenue	15653	USD
	us-gaap	Cost Of Revenue CostOfRevenue	2009	USD
CY2021Q3	us-gaap	Revenues Revenues	9245	USD
CY2020Q3	us-gaap	Revenues Revenues	2009	USD
	us-gaap	Revenues Revenues	15653	USD
	us-gaap	Revenues Revenues	2009	USD
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	94010	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1446446	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	353799	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1458507	USD
CY2021Q3	us-gaap	Professional Fees ProfessionalFees	85387	USD
CY2020Q3	us-gaap	Professional Fees ProfessionalFees	25200	USD
	us-gaap	Professional Fees ProfessionalFees	171975	USD
	us-gaap	Professional Fees ProfessionalFees	57431	USD
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	179397	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	1471646	USD
	us-gaap	Operating Expenses OperatingExpenses	525774	USD
	us-gaap	Operating Expenses OperatingExpenses	1515938	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-170152	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1469637	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-510121	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1513929	USD
CY2021Q3	us-gaap	Interest Income Operating InterestIncomeOperating	3024	USD
CY2020Q3	us-gaap	Interest Income Operating InterestIncomeOperating	0	USD
	us-gaap	Interest Income Operating InterestIncomeOperating	5556	USD
	us-gaap	Interest Income Operating InterestIncomeOperating	0	USD
CY2021Q3	us-gaap	Costs And Expenses CostsAndExpenses	8492	USD
CY2020Q3	us-gaap	Costs And Expenses CostsAndExpenses	0	USD
	us-gaap	Costs And Expenses CostsAndExpenses	11469	USD
	us-gaap	Costs And Expenses CostsAndExpenses	0	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5468	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q3	hbr	Common Shares And Warrants Issued For License Amount CommonSharesAndWarrantsIssuedForLicenseAmount	857990	USD
CY2021Q3	us-gaap	Share Based Compensation ShareBasedCompensation	69989	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-175620	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	752851	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	172843	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-55254	USD
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	55746	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5913	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-175620	USD
	us-gaap	Net Income Loss NetIncomeLoss	-516034	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1513929	USD
CY2021Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.03
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
CY2021Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20853000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	19590000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	19775038	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	19590000	shares
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-36612	USD
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	30420	USD
CY2021Q2	hbr	Common Shares And Warrants Issued For License Amount CommonSharesAndWarrantsIssuedForLicenseAmount	38500	USD
CY2021Q2	us-gaap	Share Based Compensation ShareBasedCompensation	252852	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-340414	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-44292	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	128551	USD
CY2020Q3	us-gaap	Share Based Compensation ShareBasedCompensation	1417640	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-1469637	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	76554	USD
	us-gaap	Net Income Loss NetIncomeLoss	-516034	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1513929	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	322841	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1417640	USD
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	2228	USD
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-5556	USD
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	0	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-2050	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	81120	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	826	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1231	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	0	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-1331	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	0	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-120013	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-95463	USD
	us-gaap	Increase Decrease In Notes Receivables IncreaseDecreaseInNotesReceivables	200000	USD
	us-gaap	Increase Decrease In Notes Receivables IncreaseDecreaseInNotesReceivables	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-200000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	250000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	50000	USD
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	0	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	86166	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	386166	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	66153	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-95463	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35055	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	172843	USD
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	101208	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	77380	USD
	us-gaap	Interest Paid InterestPaid	3666	USD
	us-gaap	Interest Paid InterestPaid	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	38500	USD
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	857990	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	hbr	Capitalization Of Rou Asset And Liability Operating CapitalizationOfRouAssetAndLiabilityOperating	14823	USD
	hbr	Capitalization Of Rou Asset And Liability Operating CapitalizationOfRouAssetAndLiabilityOperating	0	USD
	us-gaap	Nature Of Operations NatureOfOperations	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On September 9, 2019 (commencement of operations), Healthcare Business Resources, Inc. (“we”, “our”, the “Company”), a domestic corporation was organized in Delaware to provide consulting services to healthcare organizations. These services include management consulting related to sales, marketing, business development and advisory board function. The Company’s services are designed to help clients increase revenue, improve overall efficiency and effectiveness of their operations and grow strategically.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On March 5, 2021, HBR Pointclear, LLC, a Delaware limited liability company was incorporated. HBR Pointclear, LLC was formed to enter into an Option Agreement to Purchase Business Assets with PointClear Solutions, Inc.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On June 18, 2021, we and HBR Sub, Inc., a Delaware corporation and our wholly owned subsidiary entered into and closed an Agreement and Plan of Merger (the “Merger Agreement”), with UserTech U.S. LLC, a Delaware limited liability company (“UPlus”) and UPlus Health, LLC, a Delaware limited liability company and a wholly-owned subsidiary of UPlus (“UPlus Health”). Pursuant to the Merger Agreement, and subject to the terms and conditions contained therein, HBR Sub, Inc. was merged with and into UPlus Health, with UPlus Health surviving the merger on the terms and subject to the conditions set forth in the Merger Agreement and certain ancillary agreements. UPlus Health is now our Company’s wholly owned subsidiary. UPlus helps companies across multiple industries with continuous innovation and market development through the implementation of its proprietary technology called the U+Method, which is a is a step-by-step product development methodology that focuses on front–loading the risky parts of product development before starting large buildouts (the “U+Method Technology”). UPlus has licensed to UPlus Health the U+Method Technology and related intellectual property for use in the health care and medical services industry (the “Medical Industry”), pursuant to the license attached to the Merger Agreement as Exhibit A (the “License Agreement”). UPlus and the Company believe that their individual capabilities and expertise could be combined to provide a unique integrated solution to clients in the Medical Industry; and UPlus’ post transaction participation in providing the anticipated integrated solution is set forth in the services agreement (the “Services Agreement”), a copy of which is set forth as Exhibit B to the Merger Agreement. The Company’s post transaction financial metrics plan for UPlus Health and the anticipated integrated solution is set forth in UPlus Health’s financial metrics plan (“Financial Metrics Plan”), a copy of which is set forth as Exhibit C to the Agreement. UPlus Health will be managed by the Company’s current management team.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The consideration for the merger consisted of our Company’s issuance to UPlus of 1,000,000 shares of our common stock and a three-year warrant to purchase 1,400,000 shares of our common stock for $0.50 per share, subject to the Special Adjustments described in the Merger Agreement, which includes UPlus’ right to unwind the merger in the event we fail to meet the Financial Metrics Plan described in the Merger Agreement. As of August 31, 2021, the total purchase price for the acquisition was determined to be $857,990, which consisted of 1,000,000 shares of common stock with a fair value of $500,000 and 1,400,000 stock warrants with a fair value of $357,990. The Company concluded the transaction qualified as an asset acquisition and all such acquisition costs have been capitalized.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In this filing, unless context requires otherwise, references to “we,” “our,” “us” and “our Company” refer to Healthcare Business Resources Inc., a Delaware corporation, and its subsidiaries HBR Pointclear, LLC, HBR Business Development, LLC and UPlus Health, LLC.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Liquidity and Going Concern</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">These consolidated financial statements have been prepared on a going concern basis, which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The continuation of the Company as a going concern is dependent upon the ability of the Company to obtain equity financings to continue operations. The Company has a history of and expects to continue to report negative cash flows from operations and a net loss. Management believes that the cash on hand is sufficient to fund its planned operations into but not beyond the near term. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern twelve months from the issuance of these consolidated financial statements. These consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company may seek additional funding through a combination of equity offerings, debt financings, or other third-party funding.</p>
	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2021Q2	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	25000	USD
CY2021Q2	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	25000	USD
CY2021Q2	us-gaap	Unsecured Debt UnsecuredDebt	25000	USD
CY2021Q3	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	25000	USD
CY2021Q3	us-gaap	Unsecured Debt UnsecuredDebt	25000	USD
CY2021Q3	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	25000	USD
CY2021Q2	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	50000	USD
CY2021Q2	us-gaap	Debt Instrument Description DebtInstrumentDescription	The principal amount of $50,000 plus all interest under the $50,000 Promissory Note will be due and payable two hundred seventy (270) days from June 10, 2021. Interest on the $50,000 Promissory Note will accrue at a rate of 12.0% per annum, beginning on June 10, 2021, until the principal amount and all accrued but unpaid interest shall have been paid.
CY2021Q2	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	50000	USD
CY2021Q2	us-gaap	Unsecured Debt UnsecuredDebt	50000	USD
	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	46000	shares
	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	23000	shares
	hbr	Accredited Investors Total Consederation AccreditedInvestorsTotalConsederation	70000	USD
CY2021Q3	us-gaap	Share Price SharePrice	0.50
	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	6834	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	86166	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	322841	USD
CY2021Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	453481	USD
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	785000	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.50
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	2435000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.51
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	460000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0.50
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2760000	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.51
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	1588580	shares
	hbr	Weighted Average Remaining Term WeightedAverageRemainingTerm	5.78 years
CY2021Q3	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	200000	USD
CY2021Q3	us-gaap	Due From Related Parties DueFromRelatedParties	5556	USD
CY2021Q2	us-gaap	Debt Instrument Description DebtInstrumentDescription	Promissory Note will be due and payable two hundred seventy (270) days from the date the principal amount is received by the Company. Interest on the $25,000 Promissory Note will accrue at a rate of 12.5% per annum, beginning on the date the principal amount is received by the Company until the principal amount and all accrued but unpaid interest shall have been paid.
CY2021Q2	us-gaap	Debt Conversion Original Debt Interest Rate Of Debt DebtConversionOriginalDebtInterestRateOfDebt	0.125	pure
CY2021Q3	us-gaap	Debt Instrument Description DebtInstrumentDescription	Promissory Note will be due and payable two hundred seventy (270) days from the date the principal amount is received by the Company. Interest on the $25,000 Promissory Note will accrue at a rate of 12.0% per annum, beginning on the date the principal amount is received by the Company until the principal amount and all accrued but unpaid interest shall have been paid.
CY2021Q3	us-gaap	Debt Conversion Original Debt Interest Rate Of Debt DebtConversionOriginalDebtInterestRateOfDebt	0.120	pure
CY2021Q2	us-gaap	Debt Conversion Original Debt Interest Rate Of Debt DebtConversionOriginalDebtInterestRateOfDebt	0.120	pure
	hbr	Schedule Of Stock Warrant Activity ScheduleOfStockWarrantActivity	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Weighted </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Average </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Number of</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Warrants</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Exercise Price </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Per Share</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Outstanding at February 28, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,400,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Forfeited and expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Outstanding at August 31, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,400,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	USD
	us-gaap	Description Of Lessor Leasing Arrangements Operating Leases DescriptionOfLessorLeasingArrangementsOperatingLeases	the Company entered into a sixteen month operating lease for office space. The Company’s lease does not contain any material restrictive covenants

Files In Submission

Name	View Source	Status
0001654954-21-011307-index-headers.html	Edgar Link	pending
0001654954-21-011307-index.html	Edgar Link	pending
0001654954-21-011307.txt	Edgar Link	pending
0001654954-21-011307-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
hbr-20210831.xsd	Edgar Link	pending
hbr-20210831_cal.xml	Edgar Link	unprocessable
hbr-20210831_def.xml	Edgar Link	unprocessable
hbr-20210831_lab.xml	Edgar Link	unprocessable
hbr-20210831_pre.xml	Edgar Link	unprocessable
hbr_10q.htm	Edgar Link	pending
hbr_10q_htm.xml	Edgar Link	completed
hbr_ex109.htm	Edgar Link	pending
hbr_ex109img1.jpg	Edgar Link	pending
hbr_ex109img10.jpg	Edgar Link	pending
hbr_ex109img11.jpg	Edgar Link	pending
hbr_ex109img12.jpg	Edgar Link	pending
hbr_ex109img13.jpg	Edgar Link	pending
hbr_ex109img14.jpg	Edgar Link	pending
hbr_ex109img15.jpg	Edgar Link	pending
hbr_ex109img16.jpg	Edgar Link	pending
hbr_ex109img17.jpg	Edgar Link	pending
hbr_ex109img18.jpg	Edgar Link	pending
hbr_ex109img19.jpg	Edgar Link	pending
hbr_ex109img2.jpg	Edgar Link	pending
hbr_ex109img20.jpg	Edgar Link	pending
hbr_ex109img21.jpg	Edgar Link	pending
hbr_ex109img22.jpg	Edgar Link	pending
hbr_ex109img23.jpg	Edgar Link	pending
hbr_ex109img3.jpg	Edgar Link	pending
hbr_ex109img4.jpg	Edgar Link	pending
hbr_ex109img5.jpg	Edgar Link	pending
hbr_ex109img6.jpg	Edgar Link	pending
hbr_ex109img7.jpg	Edgar Link	pending
hbr_ex109img8.jpg	Edgar Link	pending
hbr_ex109img9.jpg	Edgar Link	pending
hbr_ex311.htm	Edgar Link	pending
hbr_ex312.htm	Edgar Link	pending
hbr_ex321.htm	Edgar Link	pending
hbr_ex322.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GFLT
GenFlat Holdings, Inc. Stock $gflt

2021 Q4 Form 10-Q Financial Statement

#000165495421011307 Filed on October 25, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GFLT GenFlat Holdings, Inc. Stock $gflt

2021 Q4 Form 10-Q Financial Statement

#000165495421011307 Filed on October 25, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GFLT
GenFlat Holdings, Inc. Stock $gflt